Ocrevus/ocrelizumab vs Briumvi

Ocrevus (ocrelizumab) is indicated for the treatment of patients with relapsing forms of multiple sclerosis (RMS). Regulators reviewed its efficacy, noting a 46% relapse rate reduction compared to Rebif in its pivotal trials. Briumvi (ublituximab-xiiy) is indicated for the treatment of relapsing forms of multiple sclerosis (MS), including clinically isolated syndrome, relapsing-remitting disease, and active secondary progressive disease, in adults. Its review highlighted an Annualized Relapse Rate (ARR) of 0.09 in its own studies.

These drugs were evaluated in separate clinical trials with distinct designs, patient populations, and timepoints. Ocrevus's review cited a relapse rate of 0.16 for ocrelizumab compared to 0.29 for Rebif. Briumvi's review reported an ARR of 0.09 for ublituximab-xiiy versus 0.23 for its comparator. The trials utilized different comparators and assessed various endpoints.

It is crucial to understand that the figures presented for Ocrevus and Briumvi are derived from independent studies and are not directly comparable. These trials had different designs, patient populations, and timepoints, and therefore, no direct comparison or implication of superiority between the two drugs can be made based on these figures.